Vaxart, Inc. cotiza a 0.44 USD y tiene una capitalización bursátil de $107M. En los últimos 12 meses ha facturado $243M con un margen de flujo de caja libre del 3.2%. Cotiza a 3.2 veces su flujo de caja libre (P/FCF) y a un PER de 2.8. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical tri…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.06 | $0.02 | $0.24 |
| Estimado | $-0.31 | $-0.21 | $0.02 | $-0.08 |
| Sorpresa | — | +71.4% | +0.0% | +400.0% |
| Métrica | VXRT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 7.6% | -38.6% | +46.2% |
| Net Margin | 6.9% | -33.6% | +40.4% |
| FCF Margin | 3.2% | -13.9% | +17.1% |
| ROE | 18.6% | -40.4% | +59.0% |
| ROA | 8.8% | -32.0% | +40.8% |
| Current Ratio | 1.57 | 2.84 | -1.27 |
| Debt / Equity | — | 0.28 | — |